PTO/SB/08a (02-09)

Approved for use through 03/31/2009. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE bond to e collection of information unlass it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to e collection of

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/524,724	
INF	ORMATIC	ON DISC	LOSURE	Filing Date	February 16, 2005	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Matthew G. Dunckley	
				Art Unit	1635	
	(Use as many	sheets as ned	essary)	Examiner Name	J. J. Zara	
Sheet	1	of	2	Attorney Docket Number	E072 1050.1	

	U.S. PATENT DOCUMENTS						
Examiner initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	Ι,	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear		
				- March - A		_	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance end not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those epplication(s) which ere marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because thet epplication was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² Sea Kinds Codes of USPTO Patent Documents et www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Stendard ST.3). ⁴ For Japanese patent documents, the indication of the year of the raign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (02-09)
Approved for use through 03/31/2009, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subst	itute for form 1449/PTO			Complete if Known		
1				Application Number	10/524,724	
IN	FORMATION	I DI	SCLOSURE	Filing Date	February 16, 2005	
ST	ATEMENT E	3Y /	APPLICANT	First Named Inventor	Matthew G. Dunckley	
				Art Unit	1635	
	(Use as many she	eets as	necessary)	Examiner Name	J. J. Zara	
Sheet	2	of	2	Attorney Docket Number	E072 1050.1	

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	1	BAUGHAN et al., "Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy," HMG Advance Access published February 19, 2009, Pages 1-48, Published by Oxford University Press.	
	2	LACERRA et al., "Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients," Proc. Natl. Acad. Sci. (PNAS) USA 97(17): 9591–9596 (2000).	
	3	SAZANI et al., "Systemically delivered antisense oligomers upregulate gene expression in mouse tissues". Nat Biotechnol. 20(12): 1228-33 (2002).	
	4	SUWANMANEE et al., "Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides," Mol. Pharmacol. 62(3):545-53 (2002).	
	5	WIRTH B., "Spinal muscular atrophy: state-of-the-art and therapeutic perspectives," ALS and Other Motor Neuron Disorders 3: 87-95 (2002).	
	6	ZHANG et al., "Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis," Nature Biotechnology 18: 862–867 (2000).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.